Adaptive Biotechnologies Corporation (ADPT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Adaptive Biotechnologies ... (ADPT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.04

-0.42 (-6.50%)

At close: Jan 14, 2025, 3:59 PM

6.20

2.56%

Pre-market Jan 15, 2025, 07:32 AM EST

undefined% (undefined)

Bid	5.5
Market Cap	892.12M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.33
PE Ratio (ttm)	-4.55
Forward PE	n/a
Analyst	Buy

Ask	6.65
Volume	795,167
Avg. Volume (20D)	1,237,803
Open	6.65
Previous Close	6.46
Day's Range	5.97 - 6.65
52-Week Range	2.28 - 7.46
Beta	undefined

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a cli...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 27, 2019

Employees 709

Stock Exchange NASDAQ

Ticker Symbol ADPT

Website https://www.adaptivebiotech.com

Analyst Forecast

According to 4 analyst ratings, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 7.53% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Adaptive Biotechnologies Corporation is scheduled to release its earnings on Feb 12, 2025, during market hours.
Analysts project revenue of $45.84M, reflecting a 0.12% YoY growth and earnings per share of -0.24, making a -20.00% decrease YoY.

Why Price Moved

2 months ago · Source

+11.51%

Adaptive Biotechnologies shares are trading higher... Unlock content with Pro Subscription

2 months ago · Source

+3.37%

Adaptive Biotechnologies shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

News

1 month ago · zacks.com

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

1 month ago · seekingalpha.com

Adaptive Biotechnologies: Making Some Progress

Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driv...

2 months ago · zacks.com

Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know

The consensus price target hints at a 31.4% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

2 months ago · seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head of IR Chad Robins - CEO and Co-Founder Ky...

2 months ago · zacks.com

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its ...

2 months ago · zacks.com

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.35 per share a year ago.